Pfizer, Novartis Learning The VALUE Of Comparative Research
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis-sponsored trial of Diovan vs. Norvasc finds no difference in cardiac morbidity and mortality. Norvasc shows better blood pressure control and fewer heart attacks, although Novartis is touting Diovan's reduction of diabetes onset. Study is the second comparative trial in recent months in which competitor-sponsored data show an advantage for Pfizer's products.
You may also be interested in...
CMS, Industry To Debate "Practical Clinical Trials" During July 20 Audio Conference
CMS Chief Medical Officer Tunis and former FDA device center director Feigal, along with J&J and Medtronic reps, will debate the benefits and pitfalls of practical clinical research during a Drug & Device Dialogue hosted by FDC Reports in partnership with Polidais LLC.
CMS, Industry To Debate "Practical Clinical Trials" During July 20 Audio Conference
CMS Chief Medical Officer Tunis and former FDA device center director Feigal, along with J&J and Medtronic reps, will debate the benefits and pitfalls of practical clinical research during a Drug & Device Dialogue hosted by FDC Reports in partnership with Polidais LLC.
VALUE Study (Correction)
The VALUE study found that fewer patients treated with Pfizer's Norvasc (amlodipine) had heart attacks (fatal and non-fatal) than patients on Novartis' Diovan (valsartan)